French Drug Company Has Made The First Vaccine Against Lyme Disease
A vaccine which could protect against Lyme disease could be available in just five years on the NHS.
Lyme disease is a condition caused by a bacteria which is carried by ticks, and it goes on to attack the nervous system.
Now, French drug manufacturer, Valneva, has completed the first-ever human trial of a vaccine against the disease, and claims the immunisation jab could be up to 96 percent effective.
David Lawrence, Valneva's chief financial officer, told the Sunday Telegraph that the company was investing £262 million ($350 million) into the development of the vaccine, attempting to make it even more effective and also making sure that it can be manufactured at a reasonable price.
Each year, the disease infects around 600,00 people a year, including around 3,000 Brits.
The number of cases is reportedly now on the rise, with Europe seeing a 14 percent increase year-on-year.
High-profile sufferers of the disease include supermodel Bella Hadid, pop-star Shania Twain and actors Alec Baldwin and Ben Stiller.
The vaccine will work by kick-starting the person's immune system to produce antibodies to directly attack the bacteria.
By targeting the gut of the tick as it's eating human blood, the vaccine will attack the bacteria hiding inside the insect so it's unable to enter the person's blood.
The early trial found the vaccine to be between 71.4 and 96.4 percent effective.
So far, there has also been 'no associated safety concerns' for patients given the vaccination.
Whilst the signs seem positive for a future vaccine, the company is also focusing on increasing its protection rate.
Some early symptoms of Lyme disease include fever, headache, muscle pain, fatigue and a ring-shaped rash.
Featured Image Credit: Pixabay